Tevogen Inc. (TVGN)
| Market Cap | 49.81M -69.9% |
| Revenue (ttm) | n/a |
| Net Income | -22.24M |
| EPS | -6.32 |
| Shares Out | 6.51M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,289 |
| Open | 7.32 |
| Previous Close | 7.80 |
| Day's Range | 7.32 - 7.65 |
| 52-Week Range | 3.64 - 43.66 |
| Beta | 0.19 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 14, 2026 |
About TVGN
Tevogen Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID pr... [Read more]
Financial Performance
Financial StatementsNews
Tevogen Bio Holdings Inc. Becomes Tevogen Inc.
WARREN, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that it will operate under the name Tevogen Inc., following approval b...
Tevogen Bio Announces 2026 Annual Meeting of Stockholders
WARREN, N.J., July 13, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) announced that its 2026 Annual Meeting of Stockholders (the “Annual Meeting)” is sched...
Tevogen files to sell 375,000 shares of common stock for holders
17:00 EDT Tevogen (TVGN) files to sell 375,000 shares of common stock for holders
Tevogen Announces Formation of a Healthcare Services Initiative
William Keane Appointed Interim Head of Initiative, Evaluating Potential Management Services Organization and Contract Research Organization Acquisitions WARREN, N.J., June 09, 2026 (GLOBE NEWSWIRE) -...
Tevogen advances strategic acquisition initiatives
Tevogen (TVGN) announced continued progress across its strategic acquisition initiatives intended to complement its existing business and support long-term financial self-sufficiency, which, if consum...
Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual Revenue
WARREN, N.J., May 28, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced continued progress across its strategic acquisition initiatives intende...
Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services Organization
WARREN, N.J., May 21, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that it has entered into a signed, non-exclusive, non-binding Letter of...
Tevogen ‘working towards’ aligning long-term incentives, performance milestones
In a letter to shareholders, CEO Ryan Saadi said, in part, “We have delivered consistent operational improvement while continuing to advance our strategic growth priorities. Loss from operations decli...
Letter to Shareholders from CEO Dr. Ryan Saadi
Tevogen highlights improved operating performance, disciplined capital allocation, pipeline growth, and evaluation of revenue-generating acquisitions.
Tevogen Bio Holdings Inc trading halted, volatility trading pause
11:45 EDT Tevogen (TVGN) Bio Holdings Inc trading halted, volatility trading pause
Tevogen Bio Holdings Inc trading resumes
11:50 EDT Tevogen (TVGN) Bio Holdings Inc trading resumes
Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest Market Close
WARREN, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that it has entered into a securities purchase agreement for a private ...
Tevogen.AI Nears Completion of PredicTcell™ Training; Initiates Commercial Readiness and Debuts Internal Application Portal
WARREN, N.J., April 27, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced continued progress within its artificial intelligence initiative, Tev...
Tevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue Growth
Potential transaction expected to add $20M+ in revenue and support double-digit growth, further strengthening Tevogen's position in oncology, rare diseases, and medical devices Target CRO operates acr...
Tevogen regains compliance with Nasdaq minimum bid price requirement
Tevogen (TVGN) received written notice from the Nasdaq notifying the company that it had regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1) for…
Tevogen Regains Compliance with Nasdaq Minimum Bid Price Requirement
WARREN, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) received written notice (the “Notification Letter”) from The Nasdaq Stock Market LLC ...
Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Speak at Microsoft Fabric Community Conference (FabCon 2026)
WARREN, N.J., March 18, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that Mittul Mehta, Chief Information Officer and Head of Tevogen.AI, ...
Tevogen Reaffirms Capital Discipline as Lead Investor Maintains Holdings and Company Limits Share Utilization
Tevogen highlights capital discipline, minimal share use, strong insider ownership, and potential acquisitions while exploring ways to reflect asset value
Tevogen reports performance advancements for Tevogen.AI platform
Tevogen (TVGN) announced performance advancements for its artificial intelligence platform, operated through Tevogen.AI. Over the past year, the company has built a proprietary database of more than 6...
Tevogen.AI Reports Advancements in PredicTcell™ Beta, Demonstrates Improved Precision Metrics and Expands Proprietary AI Infrastructure
WARREN, N.J., March 13, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced performance advancements for its artificial intelligence platform, op...
Tevogen CEO Dr. Ryan Saadi Reaffirms Clinical Commitment During International Long COVID Awareness Month; Highlights Synergies of New Leadership Team and Digital Care Platform
WARREN, N.J., March 11, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today issued a statement from Founder and CEO Dr. Ryan Saadi regarding the company's ...
Tevogen appoints interim leaders across core business verticals
Tevogen (TVGN) announced the appointment of interim leaders across its core business verticals to execute the first phase of its diversified growth strategy. In this first phase, Tevogen is evaluating...
Tevogen Names Leadership Team to Execute Diversified Growth Strategy
WARREN, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced the appointment of interim leaders across its core business verticals...
Tevogen CEO says ‘actively evaluating potential acquisitions’
Dr. Ryan Saadi, Founder & CEO Tevogen (TVGN), sent the following letter to shareholders: “Dear Shareholders, As we continue executing on Tevogen’s long-term strategy to evolve into a sustainable, reve...
Tevogen Bio Holdings Inc trading resumes
10:19 EST Tevogen (TVGN) Bio Holdings Inc trading resumes